LYSOGENE Logo

LYSOGENE

LYS | PA

Overview

Corporate Details

ISIN(s):
FR0013233475
LEI:
969500T64RILK1RD0852
Country:
France
Address:
18 RUE JACQUES DULUD, 92200 NEUILLY-SUR-SEINE
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Lysogene’s determination to succeed is rooted in our deep understanding of the impact central nervous system (CNS) diseases have on patients and families, and springs from our founder whose own child was affected by a neurodegenerative disease. Our mission is to discover and develop innovative therapies to transform the lives of people with rare central nervous system disorders. Lysogene is a biopharmaceutical gene therapy company with lead programs in neurodegenerative lysosomal storage disorders that affect children.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-05-26 17:32
Delisting Announcement
Informations privilégiées / Autres communiqués
French 84.9 KB
2023-05-26 17:32
Delisting Announcement
Inside Information / Other news releases
English 83.2 KB
2023-05-26 10:00
Delisting Announcement
Informations privilégiées / Autres communiqués
French 85.6 KB
2023-05-26 10:00
Legal Proceedings Report
Inside Information / Other news releases
English 83.5 KB
2023-05-15 18:00
Legal Proceedings Report
Inside Information / Other news releases
English 83.5 KB
2023-05-15 18:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 85.6 KB
2023-04-29 18:00
Report Publication Announcement
Inside Information / News release on accounts, results
English 82.9 KB
2023-04-29 18:00
Delisting Announcement
Informations privilégiées / Communiqué sur comptes, résultats
French 85.1 KB
2023-04-14 18:00
M&A Activity
Inside Information / Other news releases
English 83.2 KB
2023-04-14 18:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 85.4 KB
2023-03-24 20:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 95.8 KB
2023-03-24 20:00
Regulatory Filings
Inside Information / Other news releases
English 93.5 KB
2023-02-16 18:00
Delisting Announcement
Inside Information / Other news releases
English 107.8 KB
2023-02-16 18:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 110.2 KB
2023-02-03 18:00
Board/Management Information
Informations privilégiées / Autres communiqués
French 91.3 KB

Automate Your Workflow. Get a real-time feed of all LYSOGENE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for LYSOGENE

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for LYSOGENE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain
IKM
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapies for oncology & ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation platform for designing and optimizing biologic therapeutics.
United States of America
ABSI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland
ACHI
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America
ADAG

Talk to a Data Expert

Have a question? We'll get back to you promptly.